Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedJun 17, 2026
DataAggregated Company Financials
Companies65
  • 7D-3.2%
  • 3M7.5%
  • 1Y11.4%
  • YTD-14.2%

Over the last 7 days, the Life Sciences industry has dropped 3.2%, driven by Thermo Fisher Scientific declining 4.2%. Over the past 12 months, the industry was up 11%. As for the next few years, earnings are expected to grow by 17% per annum.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 18 Jun 2026US$585.9bUS$150.6bUS$13.7b40.9x42.7x3.9x
Sat, 16 May 2026US$531.5bUS$150.3bUS$14.0b31.2x37.9x3.5x
Mon, 13 Apr 2026US$561.3bUS$147.8bUS$14.1b37.3x39.8x3.8x
Wed, 11 Mar 2026US$577.0bUS$147.8bUS$14.0b33.5x41.2x3.9x
Fri, 06 Feb 2026US$635.3bUS$146.9bUS$12.6b35.2x50.4x4.3x
Sun, 04 Jan 2026US$667.9bUS$145.8bUS$12.4b36.1x54x4.6x
Tue, 02 Dec 2025US$678.1bUS$145.8bUS$12.5b36.5x54.4x4.7x
Thu, 30 Oct 2025US$646.6bUS$145.5bUS$14.5b33x44.7x4.4x
Sat, 27 Sep 2025US$544.7bUS$144.3bUS$14.6b29.4x37.4x3.8x
Mon, 25 Aug 2025US$593.8bUS$144.1bUS$14.5b29.6x41x4.1x
Wed, 23 Jul 2025US$511.5bUS$143.4bUS$8.7b36x58.9x3.6x
Fri, 20 Jun 2025US$516.1bUS$142.9bUS$9.2b35.2x56.3x3.6x
Sun, 18 May 2025US$519.6bUS$142.7bUS$9.1b33.3x57.2x3.6x
Tue, 15 Apr 2025US$514.0bUS$142.6bUS$10.0b35.4x51.6x3.6x
Thu, 13 Mar 2025US$589.6bUS$143.1bUS$9.8b37.6x60.4x4.1x
Sat, 08 Feb 2025US$668.1bUS$143.1bUS$11.1b38.1x60.2x4.7x
Mon, 06 Jan 2025US$665.5bUS$142.4bUS$10.2b43.1x65.2x4.7x
Wed, 04 Dec 2024US$675.8bUS$142.4bUS$10.2b44.8x66x4.7x
Fri, 01 Nov 2024US$672.7bUS$142.2bUS$8.8b36.6x76.2x4.7x
Sun, 29 Sep 2024US$748.6bUS$141.8bUS$8.5b40.1x88.1x5.3x
Tue, 27 Aug 2024US$744.2bUS$141.8bUS$8.5b38.3x87.9x5.2x
Thu, 25 Jul 2024US$695.7bUS$141.1bUS$12.3b40.2x56.6x4.9x
Sat, 22 Jun 2024US$684.7bUS$141.3bUS$12.2b38.6x56.2x4.8x
Mon, 20 May 2024US$741.1bUS$141.5bUS$12.4b38.2x59.6x5.2x
Wed, 17 Apr 2024US$703.0bUS$142.0bUS$12.8b42.2x55x4.9x
Fri, 15 Mar 2024US$753.0bUS$142.1bUS$12.8b44.6x58.7x5.3x
Sun, 11 Feb 2024US$708.4bUS$141.9bUS$12.7b39.7x55.7x5x
Tue, 09 Jan 2024US$684.7bUS$153.9bUS$14.2b37x48.3x4.5x
Thu, 07 Dec 2023US$648.0bUS$153.7bUS$14.0b35.3x46.3x4.2x
Sat, 04 Nov 2023US$597.3bUS$153.9bUS$11.0b31.5x54.2x3.9x
Mon, 02 Oct 2023US$672.6bUS$154.6bUS$11.2b33.3x60x4.4x
Wed, 30 Aug 2023US$733.4bUS$154.6bUS$11.2b33.4x65.4x4.7x
Fri, 28 Jul 2023US$751.7bUS$154.7bUS$11.8b30.4x63.7x4.9x
Sun, 25 Jun 2023US$690.9bUS$152.4bUS$12.5b29.3x55.3x4.5x
Price to Earnings Ratio

55.3x


Total Market Cap: US$690.9bTotal Earnings: US$12.5bTotal Revenue: US$152.4bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 56.3x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 42.7x which is lower than its 3-year average PE of 56.3x.
  • The 3-year average PS ratio of 4.4x is higher than the industry's current PS ratio of 3.9x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 3.1% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market2.32%
Healthcare-0.64%
Life Sciences-3.21%
Clinical Research and Equipment-3.21%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TECH Bio-TechneUS$55.004.8%
+US$391.4m		9.7%PE78.6x
TXG 10x GenomicsUS$32.1310.4%
+US$383.4m		195.6%PS6.4x
RGEN RepligenUS$133.552.1%
+US$157.4m		13.6%PE146.6x
ABCL AbCellera BiologicsUS$5.446.9%
+US$106.9m		56.8%PS21x
DNA Ginkgo Bioworks HoldingsUS$8.557.7%
+US$39.8m		-0.3%PS3.7x

Latest News

ABCL
US$5.44
AbCellera Biologics
7D
6.9%
1Y
56.8%
Seeking Alpha • 16h

AbCellera: An AI-Era Antibody Platform Trading For Little More Than Its Cash

Summary AbCellera, an antibody platform behind two authorized COVID-19 therapies, has rebuilt itself into a clinical-stage biotech and is one quarter away from pivotal Phase 2 data on its first wholly-owned. The deeper story is the platform: an integrated, AI-driven discovery engine that mines millions of immune cells rather than designing molecules from scratch, backed by a decade of proprietary wet lab. With more than $650M in liquidity against a roughly $1.6B market cap, investors are paying little more than cash and effectively getting the platform, the pipeline, and ~100 royalty positions. I initiate my coverage of AbCellera with a “Buy” rating, viewing it as an asymmetric, catalyst-driven bet for investors who can tolerate binary risk. Read the full article on Seeking Alpha
MRVI
US$5.22
Maravai LifeSciences Holdings
7D
2.8%
1Y
159.7%
RVTY
US$97.82
Revvity
7D
-3.4%
1Y
3.6%
Analysis Article • 21h

Revvity (RVTY) Stock Could Be 10.9% Undervalued Despite Profit And Growth Pressure

Revvity (RVTY) is back in focus after recent commentary highlighted weak organic revenue growth, declining adjusted operating profits, and ongoing annual earnings per share pressure. These factors are sharpening questions about the stock’s core business performance. See our latest analysis for Revvity. At a share price of $101.22, Revvity’s recent 30-day share price return of 7.72% and 90-day gain of 19.18% suggest momentum has picked up, even though the 5-year total shareholder return is...
TMO
US$461.69
Thermo Fisher Scientific
7D
-4.2%
1Y
17.6%
Analysis Article • 22h

Thermo Fisher Scientific (TMO) Stock Could Be 23% Below Fair Value After Neutral Rating

Piper Sandler’s new Neutral rating on Thermo Fisher Scientific (TMO), alongside a Material Transfer Agreement with Polymer Factory Sweden AB, has drawn fresh attention to how the stock reflects industry conditions and emerging technology partnerships. See our latest analysis for Thermo Fisher Scientific. Thermo Fisher Scientific’s latest share price of $472.63 sits against a mixed backdrop, with the stock down 20.23% on a year to date share price basis but delivering a 21.55% total...
WAT
US$357.00
Waters
7D
-1.7%
1Y
5.2%
Analysis Article • Jun 16

Waters (WAT) Stock Could Be 8.3% Undervalued After Product Launches And FDA Clearance

Waters (WAT) is in focus after launching its BioResolve Peptide and GTxResolve Lipid columns and securing FDA 510(k) clearance for the BD BACTEC FXI Culture System, developments that expand its biopharma and diagnostics footprint. See our latest analysis for Waters. Despite the product launches and diagnostics clearance, Waters’ share price shows mixed momentum, with a 30 day share price return of 9.51% and a 90 day share price return of 22.20%, while the 1 year total shareholder return sits...
TECH
US$55.00
Bio-Techne
7D
4.8%
1Y
9.7%
PSNL
US$9.75
Personalis
7D
3.5%
1Y
49.3%
Analysis Article • Jun 16

Personalis (PSNL) Stock Could Be 10% Undervalued After ASCO Cancer Data

Personalis (PSNL) stock is in focus after the company released new clinical data at the 2026 ASCO meeting, highlighting how its NeXT Personal test detects minimal residual disease across six solid tumor types. See our latest analysis for Personalis. The ASCO update comes after a sharp 53.93% 1 month share price return and a 37.50% 3 month share price return. The 1 year total shareholder return of 51.78% and very large 3 year total shareholder return indicate that momentum has been strong...
WST
US$323.59
West Pharmaceutical Services
7D
-2.2%
1Y
48.5%
ILMN
US$159.09
Illumina
7D
-2.1%
1Y
76.3%
Narrative Update • Jun 15

ILMN: Future Returns Will Hinge On Clinical Sequencing Momentum And Customer Stickiness

Narrative Update: Illumina The analyst price target underpinning this Illumina narrative has been raised from about $136 to $147, reflecting updated assumptions around customer stickiness, clinical sequencing momentum, and expectations for higher instrument and consumables spending highlighted in recent research. Analyst Commentary Recent research on Illumina reflects a mix of enthusiasm about the company’s position in sequencing markets and some ongoing caution around execution and valuation, with several major firms updating ratings and price targets.
IQV
US$170.67
IQVIA Holdings
7D
-6.3%
1Y
10.4%
Narrative Update • Jun 14

IQV: AI Initiatives And B2B Demand Will Support Earnings Reacceleration

IQVIA Holdings' implied fair value has been trimmed by about $1.65 to roughly $226.95, reflecting analysts' lower price targets around $210 in response to cautious sentiment on life science tools, even as they see early signs of recovery in areas like bioprocessing and quality assurance. Analyst Commentary Recent research points to a mixed setup for IQVIA Holdings, where cautious sentiment on life science tools is bumping up against early signs of recovery in specific end markets.
RGEN
US$133.55
Repligen
7D
2.1%
1Y
13.6%
Narrative Update • Jun 13

RGEN: Bioprocess Recovery And Training Hub Expansion Will Guide Future Performance

Repligen's analyst price target has been reset slightly lower to $142, as analysts factor in a modestly higher discount rate along with still-supportive views on bioprocessing demand and the broader life science tools recovery. Analyst Commentary Recent Street research around Repligen reflects a mixed setup, with several firms trimming price targets and a few others highlighting potential recovery in bioprocessing demand.
A
US$124.33
Agilent Technologies
7D
-5.5%
1Y
7.6%
DHR
US$177.76
Danaher
7D
-3.2%
1Y
-8.6%
TXG
US$32.13
10x Genomics
7D
10.4%
1Y
195.6%
Narrative Update • Jun 11

TXG: Multiomic Expansion And Spatial Launch Plans Will Shape Fairly Valued Outlook

Analysts have lifted their price targets on 10x Genomics by a range of $2 to $10, reflecting updated views on the stock. These revisions are now feeding into this valuation narrative and refined assumptions around discount rate, revenue growth, profit margins, and future P/E.
TKNO
US$4.95
Alpha Teknova
7D
10.7%
1Y
-10.2%
Narrative Update • Jun 05

TKNO: Confirmed 2026 Revenue Guidance Will Support Future Upside Potential

Analysts have slightly adjusted their price expectations for Alpha Teknova, with the updated target now reflecting modest shifts in the discount rate, forecast revenue growth, profit margins, and future P/E assumptions. Together, these factors point to a more finely tuned valuation in dollar terms.
DNA
US$8.55
Ginkgo Bioworks Holdings
7D
7.7%
1Y
-0.3%